Loading…
Clinical-stage biotech developing ion-channel drugs; lead candidate azetukalner targets epilepsy and depression.
Clinical-stage biotech developing ion-channel drugs; lead candidate azetukalner targets epilepsy and depression.
Has no approved product, so revenue is limited to occasional milestone and collaboration payments from partners; trials are funded mainly by cash raised from selling shares. Value rests on late-stage results for azetukalner, which acts on potassium channels in nerve cells.
Moat: none (IP / patents). Pre-commercial biotech; differentiation depends on azetukalner's late-stage trial results.
Headquarters: Vancouver, Canada · Founded: 1996 · Employees: 370
Size Xenon Pharmaceuticals (XENE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.79B, the 1380th largest of 3,117 United States companies the cockpit tracks. Shares closed at $57.35 on 6 Nov 2026.
Performance Over six months the shares gained 4.1%, against +2.0% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +4.5%).
Capital Return on invested capital runs 116.0 points below its cost of capital (6.4% WACC).
Short interest Short interest is 7.6% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $7.50M | $0 | $0 | $9.43M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | -$2.40M | $4.96M | -$2.56M | -$3.54M | n/a |
| EBITDA | -$439M | -$371M | -$277M | -$211M | -$128M |
| Net income | -$409M | -$346M | -$234M | -$182M | -$125M |
| Free cash flow | -$336M | -$280M | -$184M | -$151M | -$101M |
| Capital expenditure | $1.00M | $799,000 | $3.08M | $5.62M | $2.89M |
| Total debt | $6.42M | $7.94M | $9.02M | $10.9M | $10.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals XENE | $3.79B | +4% | -100% | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% |
| Supernus Pharmaceuticals SUPN | $5.43B | -49% | +16% | 45% | 4.1× | 4.2% |
| Praxis Precision Medicines PRAX | $7.75B | -16% | -100% | n/a | n/a | n/a |
| Biohaven BHVN | $2.19B | +47% | n/a | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | $6.96B | -39% | +54% | -19% | 7.9× | n/a |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 3.8× | -3.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XENE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | +6.2% | 3rd lowest of 21 |
| 6-month return | +4.1% | +2.0% | 8th highest of 20 |
| Distance from 52-week high | -21.1% | -23.8% | 10th highest of 21 |
| Revenue growth (TTM) | -100.0% | +4.5% | lowest of 19 |
| ROIC minus cost of capital | -116.0 pp | +8.0 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 0.6× | -5.3% | +7.8% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 2.8× | 6.3% | +4.5% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 1.9× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 3.4× | 7.3% | +5.9% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 2.2× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 4.5× | 1.5% | +12.1% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 2.4× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 1.8× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% | +10.6% |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 8.6× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 3.0× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 12.8× | 20.5% | +98.4% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 2.4× | 20.2% | +6.2% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 2.8× | -11.5% | +0.3% |
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | 9.3× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 5.6× | 17.8% | -5.8% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 3.1× | -2.2% | +12.0% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |